Long Grove Pharmaceuticals aims to meet the critical care needs of hospital pharmacies with the launch of premix vasopressin in its most commonly used concentrations.
Long Grove will initially enter the market with the following concentrations of premix vasopressin:
• 20 units/100 mL (0.2 units/mL) in 0.9% sodium chloride
• 40 units/100 mL (0.4 units/mL) in 0.9% sodium chloride
“We’re focusing on the areas of greatest need in critical care, and our launch of Premix Vasopressin demonstrates this commitment,” said Peter Karas, the chief commercial officer at Long Grove.
Vasopressin in sodium chloride Injection is used to increase blood pressure when other measures have failed for patients in critical hypotensive shock. Hospital pharmacies throughout the United States have a critical need for premix vasopressin with a long shelf life.
Long Grove introduced its first product to customers in 2022. The company is focused on improving the generic supply chain by developing complex formulations, addressing manufacturing challenges and achieving regulatory approvals in difficult environments.
“We believe that collaborative and reliable partnerships with manufacturers, developers, suppliers, and customers are essential for sustaining a healthy drug supply chain,” Mr. Karas explained.
Premix vasopressin ordering and contracting details will be available soon. Please visit www.longgrovepharma.com for the latest product availability information.
